Retrospective analysis of real‐world prescribing data for managing cisplatin‐based chemotherapy‐induced nausea and vomiting in China

Abstract

AbstractBackgroundThe current utilization of neurokinin‐1 receptor antagonists (NK1RAs) and the impact of updated guidelines on prescription patterns of antiemetic drugs among Chinese patients receiving highly emetogenic chemotherapy (HEC) remain undetermined. This study aims to analyze the present situation of Chinese cancer patients using antiemetic drugs and assess the appropriateness of antiemetic regimens.MethodsPrescription data were collected between January 2015 and December 2020 from cancer patients receiving cisplatin‐based chemotherapy at 76 hospitals in six major cities in China. Trends in the use of antiemetic drugs, prescribing patterns and adherence to antiemetic guidelines were assessed.ResultsAmong the 108,611 patients included in this study, 6 classes and 17 antiemetic drugs were identified as monotherapy or combination therapy in 93,872 patients (86.4%), whereas 14,739 patients (13.6%) were administered no antiemetic treatment. 5‐hydroxytryptamine 3 receptor antagonists (5‐HT3RAs) and glucocorticoids were the two most frequently used classes of antiemetics, followed by metoclopramide. NK1RAs were underused across the six cities, only 9332 (8.6%) and 1655 (1.5%) cisplatin‐based treatments were prescribed aprepitant and fosaprepitant, respectively. Prescriptions of olanzapine and lorazepam were very low throughout the study period. In prescribing patterns of antiemetic drugs, dual combination regimens were the most common (40.0%), followed by triple combination therapy and monotherapy (25.8% and 15.1%, respectively). Overall, the adherence to antiemetic guidelines for patients undergoing cisplatin‐based regimens was only 8.1% due to inadequate prescription of antiemetic drugs. Finally, our study also revealed that 5‐HT3RAs and glucocorticoids were overprescribed in 8.8% and 1.6% of patients, respectively.ConclusionsThe current study reveals suboptimal utilization of recommended antiemetic drugs for managing cisplatin‐based HEC‐induced nausea and vomiting in China. Improving the management of CINV is crucial, and these findings provide valuable insights into optimizing antiemetic drug practices.